Sitthilok Pasook, Niprapan Piangrawee, Tantiworawit Adisak, Punnachet Teerachat, Hantrakun Nonthakorn, Piriyakhuntorn Pokpong, Rattanathammethee Thanawat, Hantrakool Sasinee, Rattarittamrong Ekarat, Norasetthada Lalita, Chai-Adisaksopha Chatree
Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
PLoS One. 2025 Jan 13;20(1):e0316849. doi: 10.1371/journal.pone.0316849. eCollection 2025.
Cerebral venous sinus thrombosis (CVST) is a rare type of thrombosis that affects the cerebral venous system. The data on neurological outcomes are limited.
This study aimed to investigate the neurological outcomes of CVST, contributing factors, clinical presentation, treatment and mortality.
This was a single-center, retrospective study at a university-based referral hospital in Thailand. Consecutive patients diagnosed with CVST between January 2010 and December 2020 were included. Outcomes were neurological outcomes measured by modified Rankin Scale (mRS), anticoagulant treatment, recurrence, and mortality.
One hundred and seven CVST patients were included with a mean age (± SD) of 42.7 ± 20.4 years. Following the treatment, neurological outcomes significantly improved, with the proportion of patients with mRS 0-1 increasing from 18.7% at diagnosis to 83.2% and 85.1% at three and six months, respectively (P < 0.001). Clinical variables were associated with residual neurological symptoms (mRS≥1) included age ≥ 50 years (OR 4.1, 95% CI; 1.7-9.4, P 0.001), male sex (OR 3.0, 95%CI; 1.4-6.6, P 0.006), the thrombus involvement in deep sinus system (OR 6.1, 95%CI; 1.1-76.9, P 0.04) and cerebral vein and dural sinus thrombosis (CVT) risk score ≥ 1 (OR 3.1, 95%CI; 1.3-7.5, P 0.014). Patients whose CVST was associated with hormonal therapy were found to have a lower risk of residual neurological symptoms (OR 0.2, 95%CI 0.1-0.6, P 0.004). Hormonal therapy was associated with anticoagulant discontinuation (OR 2.7, 95% CI 1.1-7.0; P = 0.04). The presence of malignancy increased the risk of bleeding (OR 5.8, 95% CI 1.4-24.1; P 0.016). Overall mortality was 2.8%. Of which 50% were related to major bleeding.
A significant improvement in neurological outcomes was observed at 3 and 6 months after diagnosis. Older age, male sex, thrombus involvement in deep sinus system were associated with residual neurological symptoms.
脑静脉窦血栓形成(CVST)是一种影响脑静脉系统的罕见血栓形成类型。关于神经学预后的数据有限。
本研究旨在调查CVST的神经学预后、促成因素、临床表现、治疗及死亡率。
这是一项在泰国一家大学附属医院进行的单中心回顾性研究。纳入2010年1月至2020年12月期间连续诊断为CVST的患者。结局指标为采用改良Rankin量表(mRS)测量的神经学预后、抗凝治疗、复发及死亡率。
纳入107例CVST患者,平均年龄(±标准差)为42.7±20.4岁。治疗后,神经学预后显著改善,mRS 0 - 1级患者的比例从诊断时的18.7%分别增至3个月时的83.2%和6个月时的85.1%(P<0.001)。与残留神经症状(mRS≥1)相关的临床变量包括年龄≥50岁(比值比4.1,95%置信区间;1.7 - 9.4,P = 0.001)、男性(比值比3.0,95%置信区间;1.4 - 6.6,P = 0.006)、血栓累及深部静脉窦系统(比值比6.1,95%置信区间;1.1 - 76.9,P = 0.04)以及脑静脉和硬脑膜窦血栓形成(CVT)风险评分≥1(比值比3.1,95%置信区间;1.3 - 7.5,P = 0.014)。发现CVST与激素治疗相关的患者残留神经症状风险较低(比值比0.2,95%置信区间0.1 - 0.6,P = 0.004)。激素治疗与抗凝药物停用相关(比值比2.7,95%置信区间1.1 - 7.0;P = 0.04)。恶性肿瘤的存在增加了出血风险(比值比5.8,95%置信区间1.4 - 24.1;P = 0.016)。总体死亡率为2.8%。其中50%与严重出血有关。
诊断后3个月和6个月时观察到神经学预后有显著改善。年龄较大、男性、血栓累及深部静脉窦系统与残留神经症状相关。